EnGene Therapeutics raises target price to $6 from $2
ENGN•Wells Fargo raised its target price for EnGene Therapeutics to $6 from $2.
Related News
HudBay Minerals Q3 net income falls 32% to USD 151 million; revenue more than doubles to USD 765.9 million
HBM•
VinFast delivers 22,896 EVs in Vietnam in October
VFS•
Murphy Oil partners with Ratio Energies on six exploration licenses offshore Israel
MUR•
BlackRock cuts preferred share stake in Alupar to 4.964%
BLK•
NYSE American suspends trading in AtlasClear Holdings shares over low stock price
ATCH•